Clinical Evaluation of AMNIODERM+ ® Wound Dressing Containing Non-Viable Human Amniotic Membrane: Retrospective-Perspective Clinical Trial

Chronic wounds result from the body's inability to heal, causing pain, pathogen entry, limited treatment options, and societal burden. Diabetic foot ulcers are particularly challenging, often leading to severe complications like leg amputation. A clinical study tested AMNIODERM+ , a new device...

Full description

Saved in:
Bibliographic Details
Published in:Biotech (Basel) 2024-09, Vol.13 (3), p.36
Main Authors: Schmiedova, Iveta, Slama, Petr, Dembickaja, Alena, Kozova, Beata, Hyneckova, Vendula, Gogolkova, Sona, Stastna, Elen, Zahradnicek, Michal, Savic, Stefan, Davani, Arash, Hulo, Edward, Martinka, Emil
Format: Article
Language:English
Subjects:
Amniotic membrane
Amputation
Cell adhesion & migration
chronic wounds
Clinical trials
Collagen
Diabetes
Diabetes mellitus
Extracellular matrix
Feet
Fibroblasts
Foot diseases
Glucose
grassy tulle
Hyperglycemia
Hypotheses
Leg ulcers
medical device
Medical equipment
Patients
Plantar ulcers
Pressure ulcers
Trauma
tulle dressing
Vaselinum album
Wound healing
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic wounds result from the body's inability to heal, causing pain, pathogen entry, limited treatment options, and societal burden. Diabetic foot ulcers are particularly challenging, often leading to severe complications like leg amputation. A clinical study tested AMNIODERM+ , a new device with a lyophilized human amniotic membrane (HAM), on chronic diabetic foot ulcers. Participants had diabetic neuropathic or neuroischemic leg wounds (2-16 cm ) unhealed by 20% after six weeks of standard care. This study showed significant wound healing improvements with AMNIODERM+ . The median wound size reduction after 12 weeks was 95.5%, far exceeding the null hypothesis of 20% change. Additionally, 65% of patients achieved complete ulceration healing, surpassing the 50% efficacy requirement. The median time to full closure was 11.4 weeks, with the proportion of completely healed patients rising progressively, reaching 55% by week 11. These findings, from the clinical trial "Freeze-dried amniotic membrane in the treatment of nonhealing wounds", suggest AMNIODERM+ as a promising future treatment for chronic diabetic foot ulcers. The published results were obtained as part of a clinical trial entitled "Freeze-dried amniotic membrane in the treatment of nonhealing wounds: a single-arm, retrospectively-perspective clinical trial", EUDAMED Nr. CIV-SK-22-10-041146.
ISSN:2673-6284
2673-6284
DOI:10.3390/biotech13030036